NCT04573348

T Cells Response to SARS COV 2 Peptides

Prospective, One Center, Four Groups, Open, Comparative, Controlled Study to Explore T Cells Response to SARS COV 2 Peptides by Metabolic Activity Method in Convalesce and Healthy Individuals Versus Antibody Response

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 400 (estimated)
• Sponsor: Savicell Diagnostics Ltd · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

The analysis method described in this protocol is a novel simple plausible immunological approach which is non-invasive, high throughput, real-time quantitative monitoring of metabolic activity (MA) profiles of fresh Peripheral Blood Mononuclear Cells (PBMC) in response to various reagents at different concentrations. The purpose of this study is to evaluate the T cells reactivity to SARS COV 2 immunogenic selected peptides by Metabolic Activity Method in convalesce and healthy individuals and to compare it with Antibody response (ELISA) and clinical information

Detailed description

This is a prospective, four groups, open, comparative, controlled study. A total of 400 completed, evaluated subjects will be enrolled in this study. Main Study Measures: Reactivity of T cells to selected SARS COV-2 peptides by MA test and IgG Antibody response to SARS COV-2 by commercial ELISA test. Study Procedures: * Screening * Informed consent signing * Medical history review * Blood collection. * MA test and ELISA test will be performed at Savicell's Laboratory site.

Conditions

• Covid19
• Corona Virus Infection

Interventions

Type	Name	Description
DIAGNOSTIC_TEST	Savicell's ImmunoBiopsy™	ImmunoBiopsy and ELISA

Timeline

• Start date: 2020-10-14
• Primary completion: 2021-05-10
• Completion: 2021-10-10
• First posted: 2020-10-05
• Last updated: 2020-11-02

Locations

1 site across 1 country: Israel